Colorectal Cancer Screening with Faecal Immunochemical Test: Patterns of Participation

Overview

Journal J Med Screen

Specialty Public Health

Date 2023 Jul 19

PMID 37464838

Authors

Hanna Heyman

Johannes Blom

Deborah Saraste

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate participation and participation patterns in a population-based screening programme for colorectal cancer (CRC) using the faecal immunochemical test (FIT).

Methods: All individuals invited to three consecutive screening rounds in the population-based CRC screening between October 2015 and December 2020 in the Stockholm-Gotland Region, Sweden were included. Patterns of participation were assessed.

Results: The study included 26 541 individuals which resulted in 79 623 screening events. The overall uptake rate was 71.5% and women had a significantly higher participation rate. The participation rate increased significantly between the first and third screening round for both men and women, and the increase was larger among men than women (66.1 to 70.7% . 73.1 to 75.4%). In total, 80.9% participated at least once. Consistent participation was the most common participation pattern (61.0%). The probability of attending all three consecutive rounds after initial participation was 87.7%. Over the three rounds, 17.4% participated after a reminder letter. Screening individuals attending after a reminder letter had a higher proportion of drop-outs in the following screening round compared to initial participants (15.4% vs 6.2%).

Conclusion: A constant and high participation rate was observed in population-based FIT-screening for CRC. Initial participation was a strong predictor for continuous participation. The need for a reminder letter before participation was a risk factor for subsequent drop-out.

References

Steele R, McClements P, Libby G, Carey F, Fraser C . Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer. Colorectal Dis. 2013; 16(1):28-32. DOI: 10.1111/codi.12393. View

Saraste D, Ohman D, Sventelius M, Elfstrom K, Blom J, Tornberg S . Initial participation as a predictor for continuous participation in population-based colorectal cancer screening. J Med Screen. 2017; 25(3):126-133. DOI: 10.1177/0969141317717757. View

Lo S, Halloran S, Snowball J, Seaman H, Wardle J, Von Wagner C . Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut. 2014; 64(2):282-91. PMC: 4316922. DOI: 10.1136/gutjnl-2013-306144. View

Blom J, Lowbeer C, Elfstrom K, Sventelius M, Ohman D, Saraste D . Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate. J Med Screen. 2018; 26(2):92-97. DOI: 10.1177/0969141318804843. View

van der Vlugt M, Grobbee E, Bossuyt P, Bongers E, Spijker W, Kuipers E . Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br J Cancer. 2016; 116(1):44-49. PMC: 5220157. DOI: 10.1038/bjc.2016.399. View

Klabunde C, Blom J, Bulliard J, Garcia M, Hagoel L, Mai V . Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015; 22(3):119-26. DOI: 10.1177/0969141315584694. View

Le Pimpec F, Moutel G, Piette C, Lievre A, Bretagne J . Fecal immunological blood test is more appealing than the guaiac-based test for colorectal cancer screening. Dig Liver Dis. 2017; 49(11):1267-1272. DOI: 10.1016/j.dld.2017.08.018. View

Steele R, Kostourou I, McClements P, Watling C, Libby G, Weller D . Effect of gender, age and deprivation on key performance indicators in a FOBT-based colorectal screening programme. J Med Screen. 2010; 17(2):68-74. DOI: 10.1258/jms.2010.009120. View

Blom J, Kilpelainen S, Hultcrantz R, Tornberg S . Five-year experience of organized colorectal cancer screening in a Swedish population - increased compliance with age, female gender, and subsequent screening round. J Med Screen. 2014; 21(3):144-50. DOI: 10.1177/0969141314545555. View

10.

Moss S, Mathews C, Day T, Smith S, Seaman H, Snowball J . Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut. 2016; 66(9):1631-1644. DOI: 10.1136/gutjnl-2015-310691. View

11.

Ventura L, Mantellini P, Grazzini G, Castiglione G, Buzzoni C, Rubeca T . The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis. 2013; 46(1):82-6. DOI: 10.1016/j.dld.2013.07.017. View

12.

Vart G, Banzi R, Minozzi S . Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med. 2012; 55(2):87-92. DOI: 10.1016/j.ypmed.2012.05.006. View

13.

Hewitson P, Glasziou P, Irwig L, Towler B, Watson E . Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007; (1):CD001216. PMC: 6769059. DOI: 10.1002/14651858.CD001216.pub2. View

14.

Chiu H, Chen S, Yen A, Chiu S, Fann J, Lee Y . Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015; 121(18):3221-9. PMC: 4676309. DOI: 10.1002/cncr.29462. View

15.

Hultgren R, Elfstrom K, Ohman D, Linne A . Long-Term Follow-Up of Men Invited to Participate in a Population-Based Abdominal Aortic Aneurysm Screening Program. Angiology. 2020; 71(7):641-649. DOI: 10.1177/0003319720921741. View

16.

Osborne J, Wilson C, Duncan A, Cole S, Flight I, Turnbull D . Patterns of participation over four rounds of annual fecal immunochemical test-based screening for colorectal cancer: what predicts rescreening?. BMC Public Health. 2017; 18(1):81. PMC: 5540393. DOI: 10.1186/s12889-017-4634-8. View

17.

Baldacchini F, Bucchi L, Giuliani O, Mancini S, Ravaioli A, Vattiato R . Results of Compliant Participation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer. Clin Gastroenterol Hepatol. 2020; 19(11):2361-2369. DOI: 10.1016/j.cgh.2020.08.038. View

18.

von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I . European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2012; 45(1):51-9. PMC: 4482205. DOI: 10.1055/s-0032-1325997. View

19.

Steele R, Kostourou I, McClements P, Watling C, Libby G, Weller D . Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening. BMJ. 2010; 341:c5531. PMC: 2965320. DOI: 10.1136/bmj.c5531. View

20.

Breekveldt E, Lansdorp-Vogelaar I, Toes-Zoutendijk E, Spaander M, van Vuuren A, van Kemenade F . Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. Lancet Gastroenterol Hepatol. 2021; 7(1):60-68. DOI: 10.1016/S2468-1253(21)00368-X. View